SCHEMBL24617273

SCHEMBL24617273

O=c1c2ccc(-c3ccncc3)cc2ccn1Cc1cccc(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 4/20 0.50
▸ ROCK2 O75116 3/20 0.50
▸ HTR6 P50406 1/20 0.49
▸ GRK2 P25098 1/20 0.47
▸ GRM2 Q14416 2/20 0.47
▸ HSD17B1 P14061 1/20 0.46
▸ HSD17B2 P37059 1/20 0.46
▸ CYP17A1 P05093 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP11B1 P15538 2/20 0.43
▸ CYP11B2 P19099 2/20 0.43
▸ CYP19A1 P11511 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ DHPS P49366 1/20 0.42
▸ PRKACA P17612 2/20 0.40
▸ PRKACG P22612 1/20 0.40
▸ PRKACB P22694 1/20 0.40
▸ NLRP3 Q96P20 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31006530 0.87 HTR6 (0.64) ROCK1ROCK2HTR6GRK2GRM2
SCHEMBL29283812 0.87 HTR6 (0.64) ROCK1ROCK2HTR6GRK2GRM2
SCHEMBL24617269 0.84 ROCK2 (0.71) ROCK1ROCK2HTR6GRK2GRM2
SCHEMBL29283797 0.83 HSP90AB1 (0.51) ROCK1ROCK2HTR6GRM2HSD17B1
SCHEMBL31006556 0.83 HSP90AB1 (0.51) ROCK1ROCK2HTR6GRM2HSD17B1
SCHEMBL24617319 0.83 ROCK2 (0.59) ROCK1ROCK2GRK2GRM2
SCHEMBL24616951 0.82 ROCK2 (0.47) ROCK1ROCK2HTR6GRK2GRM2
SCHEMBL24616890 0.82 ROCK2 (0.46) ROCK1ROCK2GRM2HSP90AB1DHPS
SCHEMBL31006529 0.81 HSP90AB1 (0.53) ROCK1ROCK2HTR6GRK2GRM2
SCHEMBL29283816 0.81 HSP90AB1 (0.53) ROCK1ROCK2HTR6GRK2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 — — US claimed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 — — CN claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 — — US disclosed
CN-117136186-A Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof 盖诺斯克公司 2023-11-28 — — CN disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 ROCK1 2/4885ROCK2 1/4885HTR6 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback